“Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s758. doi:10.25251/0bnq3318.